US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Sage Therapeutics Inc (SAGE)
Sage Therapeutics Inc (SAGE) ニュース

SAGE

Sage Therapeutics (SAGE)

Sage Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SAGE

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/07	19 : 30	Business Wire	Sage Therapeutics to Participate in Upcoming May Investor Conferences	NASDAQ:SAGE	Sage Therapeutics Inc
2024/04/25	19 : 30	Business Wire	Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress	NASDAQ:SAGE	Sage Therapeutics Inc
2024/04/17	19 : 30	Business Wire	Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease	NASDAQ:SAGE	Sage Therapeutics Inc
2024/04/11	19 : 30	Business Wire	Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/28	20 : 30	Business Wire	Sage Therapeutics to Present at Upcoming March Investor Conferences	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/22	06 : 35	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/16	07 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/16	07 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/15	06 : 09	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/14	21 : 49	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/14	21 : 20	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/14	20 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/14	20 : 30	Business Wire	Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/01	07 : 25	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/01	06 : 50	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SAGE	Sage Therapeutics Inc
2024/01/31	20 : 30	Business Wire	Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024	NASDAQ:SAGE	Sage Therapeutics Inc
2024/01/25	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SAGE	Sage Therapeutics Inc
2024/01/23	22 : 13	Edgar (US Regulatory)	Form SC TO-I - Tender offer statement by Issuer	NASDAQ:SAGE	Sage Therapeutics Inc
2024/01/08	20 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SAGE	Sage Therapeutics Inc
2024/01/08	20 : 32	Business Wire	Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:SAGE	Sage Therapeutics Inc
2024/01/08	20 : 30	Business Wire	Sage Therapeutics Announces Changes to Board of Directors	NASDAQ:SAGE	Sage Therapeutics Inc
2024/01/05	06 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc
2024/01/02	20 : 30	Business Wire	Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024	NASDAQ:SAGE	Sage Therapeutics Inc
2023/12/19	22 : 32	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:SAGE	Sage Therapeutics Inc
2023/12/19	22 : 30	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:SAGE	Sage Therapeutics Inc
2023/12/14	20 : 30	GlobeNewswire Inc.	ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.	NASDAQ:SAGE	Sage Therapeutics Inc
2023/12/14	20 : 30	Business Wire	ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.	NASDAQ:SAGE	Sage Therapeutics Inc
2023/12/08	23 : 00	Edgar (US Regulatory)	Form SC TO-C - Written communication relating to an issuer or third party	NASDAQ:SAGE	Sage Therapeutics Inc
2023/12/08	22 : 30	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:SAGE	Sage Therapeutics Inc
2023/11/08	20 : 30	Business Wire	Sage Therapeutics to Present at Upcoming November Investor Conferences	NASDAQ:SAGE	Sage Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:SAGE

1 2 3 4 5 6 7 8 9 10 次へ >>

BNP Paribas (QX)

Health Care Select Sector

Invesco QQQ Trust Series 1

Financial Select Sector

US Dollar vs Yen

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約